Preclinical Efficacy of the Combination of Met and Src Family Kinase Inhibitors in Triple-Negative Breast Cancer.

被引：0
|
作者：
Gartner, E. M. [1 ]
Kim, E. M. H. [1 ]
Choi, L. [1 ]
Boerner, J. [1 ]
机构：
[1] Wayne State Univ, Karmanos Canc Ctr, Detroit, MI USA
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/0008-5472.SABCS11-P008-08
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD08-08
引用
收藏
页数：1
相关论文
共 50 条
  • [21] PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer
    Geenen, Jill J. J.
    Linn, Sabine C.
    Beijnen, Jos H.
    Schellens, Jan H. M.
    [J]. CLINICAL PHARMACOKINETICS, 2018, 57 (04) : 427 - 437
  • [22] PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer
    Jill J. J. Geenen
    Sabine C. Linn
    Jos H. Beijnen
    Jan H. M. Schellens
    [J]. Clinical Pharmacokinetics, 2018, 57 : 427 - 437
  • [23] Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer
    El Guerrab, Abderrahim
    Bamdad, Mahchid
    Kwiatkowski, Fabrice
    Bignon, Yves-Jean
    Penault-Llorca, Frederique
    Aubel, Corinne
    [J]. ONCOTARGET, 2016, 7 (45) : 73618 - 73637
  • [24] Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
    Silver, Daniel P.
    Richardson, Andrea L.
    Eklund, Aron C.
    Wang, Zhigang C.
    Szallasi, Zoltan
    Li, Qiyuan
    Juul, Nicolai
    Leong, Chee-Onn
    Calogrias, Diana
    Buraimoh, Ayodele
    Fatima, Aquila
    Gelman, Rebecca S.
    Ryan, Paula D.
    Tung, Nadine M.
    De Nicolo, Arcangela
    Ganesan, Shridar
    Miron, Alexander
    Colin, Christian
    Sgroi, Dennis C.
    Ellisen, Leif W.
    Winer, Eric P.
    Garber, Judy E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (07) : 1145 - 1153
  • [25] Preclinical efficacy of dasatinib in combination with PARP inhibitor plus standard cytotoxic agent in triple-negative breast cancer xenograft model
    Sun, Y.
    Lin, X.
    Carlson, Jh
    De, P.
    Dey, N.
    Williams, C.
    Leyland-Jones, B.
    [J]. CANCER RESEARCH, 2017, 77
  • [26] The efficacy of betulinic acid in triple-negative breast cancer
    Weber, Daniel
    Zhang, Mixia
    Zhuang, Pengwei
    Zhang, Yanjun
    Wheat, Janelle
    Currie, Geoffrey
    Al-Eisawi, Zaynab
    [J]. SAGE OPEN MEDICINE, 2014, 2
  • [27] Design and synthesis of dual BRD4/Src inhibitors for treatment of triple-negative breast cancer
    Wang, Ying
    Huang, Aima
    Chen, Lu
    Sun, Fan
    Zhao, Man
    Zhang, Ming
    Xie, Yubao
    Xu, Shiyu
    Li, Min
    Hong, Liang
    Li, Guofeng
    Wang, Rui
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 264
  • [28] Comprehensive kinome activity mapping of triple-negative breast cancer.
    Koemans, Nina M.
    Van der Borden, Carolien L.
    Mori, Miki
    Pan, Bo
    Wang, Changjun
    Van 't Veer, Laura J.
    Coppe, Jean-Philippe
    [J]. MOLECULAR CANCER RESEARCH, 2018, 16 (08) : 44 - 44
  • [29] Safety and efficacy of eribulin in combination with gemcitabine in patients with advanced triple negative breast cancer.
    Michalaki, Vasiliki
    Fragulidis, Georgios
    Kondis, Ioannis
    Karvouni, Eleni
    Dafnios, Nikolaos
    Kotsiou, Antonia
    Vassiliou, Ioannis
    Papadimitriou, Christos
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [30] Pre-clinical combination of a PARP inhibitor, talazoparib, and carboplatin in triple-negative breast cancer.
    Cotte, Alexia
    Beniey, Michele
    Haque, Takrima
    Bechir, Nelly
    Hubert, Audrey
    Diallo, Korotoum W.
    Tran-Thanh, Danh
    Hassan, Saima N.
    [J]. CANCER RESEARCH, 2021, 81 (13)
12345